ARCHIVES

Tissue of Origin Test Consistent With Diagnosis In Blinded Validation Study

This article is from The Cancer Letter archive.

Vol. 34 No. 1 | January 28, 2011

Download PDF Visit The Full Archive

Related Articles

In Brief: Lasker Foundation Will Not Make 1990 Awards; Michigan Cancer Elects Fischer Vice Chairman

March 2, 1990

Sprycell Approved for CML

November 5, 2010

Also in this 12-page issue: NCI gives Doroshow and Fine “lead role” in clinical trials system review.

November 14, 2003

University of Kansas Cancer Center Receives NCI Center Designation

July 13, 2012

Funding Opportunities

February 28, 2003

Next issue of The Cancer Letter is scheduled for Jan. 7, 2005.

December 10, 2004